Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NRAS-Mutated Rhabdomyosarcoma Cells Are Vulnerable to Mitochondrial Apoptosis Induced by Coinhibition of MEK and PI3Kα.

Cancer research - 15 Apr 2018

Dolgikh Nadezda, Hugle Manuela, Vogler Meike, Fulda Simone

Abstract excerpt

Sequencing studies have revealed recurrent mutations in the RAS pathway in rhabdomyosarcoma (RMS). However, RAS effector pathways in RMS are poorly defined. Here, we report that coinhibition of NRAS or MEK plus PI3Kα triggers widespread apoptosis in NRAS-mutated RMS cells. Subtoxic concentrations of the MEK inhibitor MEK162 and the PI3Kα-specific inhibitor BYL719 synergized to trigger apoptosis in NRAS-mutated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Caspases
Share to Gene Silencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Kinase Kinases

Share to Proto-Oncogene Proteins c-bcl-2

Share to Rhabdomyosarcoma

Share to RNA Caps

Share to Thiazoles

Source

Identifiers

PMID: 29437705
DOI: 10.1158/0008-5472.CAN-17-1737

Genes

NRAS
BMF
HRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NRAS-Mutated Rhabdomyosarcoma Cells Are Vulnerable to Mitochondrial Apoptosis Induced by Coinhibition of MEK and PI3Kα.PMID 29437705Read ↗

Combined Inhibition of HRAS and MEK Induces Tumor Regression and Restores Myogenic Differentiation in HRAS-Mutant Rhabdomyosarcoma.Semantic proximity Read ↗

Daraxonrasib (RMC-6236) is an effective targeted therapy for <i>RAS</i> -mutant neuroblastomaSemantic proximity Read ↗

Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK.Semantic proximity Read ↗

Sensitization to Ionizing Radiation by MEK inhibition is Dependent on SNAI2 in Fusion-negative RhabdomyosarcomaSemantic proximity Read ↗

Clinicopathologic and survival correlates of embryonal rhabdomyosarcoma driven by RAS/RAF mutations.Semantic proximity Read ↗

Efficacy of RMC-6236 (Daraxonrasib) and novel combination strategies targeting resistance in RAS pathway-driven neuroblastomaSemantic proximity Read ↗

Targeting inhibitor of apoptosis proteins (IAPs) with IAP inhibitors sensitises malignant rhabdoid tumour cells to cisplatinSemantic proximity Read ↗

Dual Targeting of MAPK Signaling and Senescence-Associated Survival Pathways Overcomes Vincristine Resistance in Fusion-Negative RhabdomyosarcomaSemantic proximity Read ↗

Identification of a novel synthetic lethality of combined inhibition of hedgehog and PI3K signaling in rhabdomyosarcomaSemantic proximity Read ↗

Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevanceSemantic proximity Read ↗

Efficacy of the MEK1/2 inhibitor trametinib in combination with clinically-investigated γ-secretase inhibitors in rhabdomyosarcomaSemantic proximity Read ↗

Neuroblastoma: oncogenic mechanisms and therapeutic exploitation of necroptosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.